

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:366560-2020:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products  
2020/S 149-366560**

**Contract notice**

**Supplies**

**Legal Basis:**

Directive 2014/24/EU

**Section I: Contracting authority**

**I.1) Name and addresses**

Official name: The NHS Commissioning Board (operating under the name of NHS England)

Postal address: 2nd Floor, Rutland House

Town: Runcorn

NUTS code: UK UNITED KINGDOM

Postal code: LS1 7UE

Country: United Kingdom

E-mail: [lynne.tierney@nhs.net](mailto:lynne.tierney@nhs.net)

**Internet address(es):**

Main address: <https://nhsengland.bravosolution.co.uk>

**I.2) Information about joint procurement**

The contract is awarded by a central purchasing body

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://nhsengland.bravosolution.co.uk>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://nhsengland.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the abovementioned address

**I.4) Type of the contracting authority**

Ministry or any other national or federal authority, including their regional or local subdivisions

**I.5) Main activity**

Health

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title:**

NHS National Pharmaceuticals Transition 2020\_2

Reference number: CM/PHG/20/5618

**II.1.2) Main CPV code**

33600000 Pharmaceutical products

**II.1.3) Type of contract**

Supplies

**II.1.4) Short description:**

NHS National Pharmaceuticals Transition 2020\_2

Offer reference number: CM/PHG/20/5618

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)

Potential periods of call-offs under the framework agreement

Transition products:

LSNE 1 December 2020 to 30 September 2021 (10 months)

NWLN 1 December 2020 to 31 January 2022 (14 months)

CESW 1 December 2020 to 30 June 2022 (19 months)

Hospital only products:

All Regions 1 December 2020 to 31 January 2022 (14 months)

Products on the framework include (but are not limited to):

Ambrisentan

Deferiprone

Fosaprepitant

Micafungin

Noradrenaline (RTU presentations only)

Oseltamivir

Oxycodone/Naloxone (combination)

Prasugrel

Solifenacin

Temsirolimus

Thalidomide

Tipranavir

Tolvaptan

Co-Amoxiclav

Valganciclovir

Valaciclovir

Piperacillin/Tazobactam Pdr for Inj Vial 4g/500mg

II.1.5) **Estimated total value**

Value excluding VAT: 86 600 000.00 GBP

II.1.6) **Information about lots**

This contract is divided into lots: yes

Tenders may be submitted for all lots

II.2) **Description**

II.2.1) **Title:**

Transition 2020\_2 — Transition Products for LSNE Region 1 December 2020 to 30 September 2021 (10 Months)

Lot No: 01

II.2.2) **Additional CPV code(s)**

33600000 Pharmaceutical products

33690000 Various medicinal products

II.2.3) **Place of performance**

NUTS code: UK UNITED KINGDOM

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Pharmaceuticals Transition 2020\_2

Offer reference number: CM/PHG/20/5618

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months).

Potential periods of call-offs under the framework agreement

Transition products:

LSNE 1 December 2020 to 30 September 2021 (10 months)

NWLN 1 December 2020 to 31 January 2022 (14 months)

CESW 1 December 2020 to 30 June 2022 (19 months)

Hospital only products:

All Regions 1 December 2020 to 31 January 2022 (14 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/12/2020

End: 30/09/2021

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework lot has options to extend for periods of up to a maximum of 10 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Transition 2020\_2 — Transition Products for NWLN Region 1 December 2020 to 31 January 2022 (14 Months)

Lot No: 02

II.2.2) **Additional CPV code(s)**

33600000 Pharmaceutical products

33690000 Various medicinal products

II.2.3) **Place of performance**

NUTS code: UK UNITED KINGDOM

II.2.4) **Description of the procurement:**

NHS National Pharmaceuticals Transition 2020\_2

Offer reference number: CM/PHG/20/5618

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months).

Potential periods of call-offs under the framework agreement.

Transition products:

LSNE 1 December 2020 to 30 September 2021 (10 months)

NWLN 1 December 2020 to 31 January 2022 (14 months)

CESW 1 December 2020 to 30 June 2022 (19 months)

Hospital only products:

All Regions 1 December 2020 to 31 January 2022 (14 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/12/2020

End: 31/01/2022

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework lot has options to extend for periods of up to a maximum of 14 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Transition 2020\_2 — Transition Products for CESW Region 1 December 2020 to 30 June 2022 (19 Months)

Lot No: 03

II.2.2) **Additional CPV code(s)**

33600000 Pharmaceutical products

33690000 Various medicinal products

II.2.3) **Place of performance**

NUTS code: UK UNITED KINGDOM

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Pharmaceuticals Transition 2020\_2

Offer reference number: CM/PHG/20/5618

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months).

Potential periods of call-offs under the framework agreement

Transition products:

LSNE 1 December 2020 to 30 September 2021 (10 months)

NWLN 1 December 2020 to 31 January 2022 (14 months)

CESW 1 December 2020 to 30 June 2022 (19 months)

Hospital only products:

All Regions 1 December 2020 to 31 January 2022 (14 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/12/2020

End: 30/06/2022

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework lot has options to extend for periods of up to a maximum of 19 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Transition 2020\_2 — Hospital Only Products for all Regions 1 December 2020 to 31 January 2022 (14 Months)

Lot No: 04

II.2.2) **Additional CPV code(s)**

33600000 Pharmaceutical products

33690000 Various medicinal products

II.2.3) **Place of performance**

NUTS code: UK UNITED KINGDOM

II.2.4) **Description of the procurement:**

NHS National Pharmaceuticals Transition 2020\_2

Offer reference number: CM/PHG/20/5618

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)

Potential periods of call-offs under the framework agreement

Transition products:

LSNE 1 December 2020 to 30 September 2021 (10 months)

NWLN 1 December 2020 to 31 January 2022 (14 months)

CESW 1 December 2020 to 30 June 2022 (19 months)

Hospital only products:

All Regions 1 December 2020 to 31 January 2022 (14 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/12/2020

End: 31/01/2022

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework lot has options to extend for periods of up to a maximum of 14 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

**Section III: Legal, economic, financial and technical information**

III.1) **Conditions for participation**

III.1.1) **Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers**

III.1.2) **Economic and financial standing**

III.1.3) **Technical and professional ability**

III.1.5) **Information about reserved contracts**

III.2) **Conditions related to the contract**

III.2.2) **Contract performance conditions:**

III.2.3) **Information about staff responsible for the performance of the contract**

**Section IV: Procedure**

IV.1) **Description**

IV.1.1) **Type of procedure**

Open procedure

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement  
Framework agreement with several operators

IV.1.4) **Information about reduction of the number of solutions or tenders during negotiation or dialogue**

IV.1.6) **Information about electronic auction**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

IV.2.2) **Time limit for receipt of tenders or requests to participate**

Date: 03/09/2020

Local time: 13:00

IV.2.3) **Estimated date of dispatch of invitations to tender or to participate to selected candidates**

IV.2.4) **Languages in which tenders or requests to participate may be submitted:**

English

IV.2.6) **Minimum time frame during which the tenderer must maintain the tender**

IV.2.7) **Conditions for opening of tenders**

Date: 03/09/2020

Local time: 13:00

Place:

Runcorn

Information about authorised persons and opening procedure:

Commercial Medicines Unit employee

**Section VI: Complementary information**

VI.1) **Information about recurrence**

This is a recurrent procurement: no

VI.2) **Information about electronic workflows**

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) **Additional information:**

#### Responding to this notice

Any supplier may be disqualified who does not respond to the following in the requisite manner:

##### 1) Submission of expression of interest and procurement specific information

This procurement exercise will be conducted on the eTendering portal at <https://nhsengland.bravosolution.co.uk>.

Candidates wishing to be considered for this procurement exercise must register, and provide additional Procurement specific information (if requested), through the eTendering portal as follows:

##### 1.1) If not already registered, Candidates should register on the eTendering portal at

<https://nhsengland.bravosolution.co.uk/web/login.html> and click the link to register:

- accept the terms and conditions and click continue,
- enter your correct business and user details,
- note the username you chose and click 'Save' when complete,
- you will shortly receive an email with your unique password (please keep this secure).

##### 1.2) Once registered, candidates must express interest as follows:

- (a) login to the eTendering portal;
- (b) select 'Response to ITT';
- (c) select 'ITTs Open To All Suppliers';
- (d) access listing related to this procurement, NHS National Pharmaceuticals Transition 2020\_2, and view details;
- (e) click on 'Express interest' button at the top of the page.
- (f) once you have expressed interest, the ITT will move to 'My ITTs', where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the 'Publish' button.

##### 1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or [help@bravosolution.co.uk](mailto:help@bravosolution.co.uk)

##### 2) General supplier information.

To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page <https://supplierregistration.cabinetoffice.gov.uk> and select 'Register' at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at: [support@nqc.com](mailto:support@nqc.com) or telephone +44 (0) 845 299 2994.

##### Other contracting authorities

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

#### VI.4) **Procedures for review**

##### VI.4.1) **Review body**

Official name: The Royal Courts of Justice  
Town: London or any other district registry of the High Court  
Country: United Kingdom

- VI.4.2) **Body responsible for mediation procedures**
- VI.4.3) **Review procedure**
- VI.4.4) **Service from which information about the review procedure may be obtained**
- VI.5) **Date of dispatch of this notice:**  
30/07/2020